HopeStage
Back to all studies
CompletedNCT00880919

Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD)

This study is completed. It focuses on personality disorders and currently lists study information in the United States.

Personality disorders, Borderline personalityDrugFrom 18 Years to 45 Years
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 45 years.

Listed locations
Iowa City, United States · Belmont, United States and 1 more locationSee all locations and recruitment

Compensation and expense reimbursement have not been verified for this summary.

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateJune 2008
Recruitment status
Completed
Enrollment listed in the registry
95
Sponsor
University of Minnesota
Sponsor type
University
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 18 Years to 45 Years
Official registry ID
NCT00880919
Official title
Seroquel XR for the Management of Borderline Personality Disorder (BPD)

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: NCT00880919. We help you review the study, but cannot decide medical eligibility.

Recruitment & locations

Completed

Iowa City · Belmont · Minneapolis

Registry details
Registry conditions (original wording)

Borderline Personality Disorder

A listed location does not confirm current availability.

FAQ

Questions about this study

Who is behind this study?

The study sponsor is University of Minnesota, a university.

Does this study involve medication?

Yes. The study involves medication, including quetiapine extended-release and Placebo.

Who can participate?

Listed age limits: 18 years to 45 years.

Is this study still recruiting?

The registry lists this study as completed.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me